Bausch Sees Sales Drivers In Lumify, Ocuvite And PreserVision Line Extensions
Lumify reached 35% market share in US OTC eye drops and Ocuvite and Preservision vision health supplements are the No. 2 sales driver across Bausch's total portfolio.
You may also be interested in...
Bausch says it expects US FDA to approve its ANDA for the first preservative-free OTC eye drop for ocular itching associated with allergic conjunctivitis in the second half of 2020. The firm reports its Lumify redness relief drops generated sales of $63m for 2019.
Lumify redness relief eye drops nearly doubled in sales between Bausch's second and third quarters and drove 7% organic growth of its global consumer business compared to the year-ago period. The brand has double the market share of its two closest competitors, and the firm plans clinical studies for product extensions to the brand in 2020.
Ensure, Glucerna brands boost Abbott Nutrition adult product third-quarter sales 3.9% on reported basis to $830m; Baush + Lomb relaunches PreserVision AREDS 2 Formula soft gels with easier-to-swallow option; Hum Nutrition Mighty Night supplement boosts skin cell renewal during sleep; and NOW Health Group acquires family-owned SuperNutrition.